Security key
810648105
scPharmaceuticals Inc. - Common Stock, par value $0.0001 per share (SCPH)
CUSIP: 810648105
Q2 2018 13F Holders as of 30 Jun 2018
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Total 13F shares
- 8,090,838
- Total 13F value
- $45,789,211
- Share change
- -226,630
- SEC-reported price per share
- $5.66
- Number of holders
- 37
- Value change
- -$6,149,684
- Number of buys
- 26
- Number of sells
- 13
- Shares outstanding
- 53,364,241
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2018
Institutions
37
Top holders
10
SCPH full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2018
Previous quarter: Q1 2018
scPharmaceuticals Inc. SEC filings
scPharmaceuticals Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 810648105
Recent filing periods:
Ownership snapshot
Top reported holders of SCPH - scPharmaceuticals Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ORBIMED ADVISORS LLC
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
15/15
Latest evidence
31 Mar 2018
13F
Lead comparable stake: 6.4%
Showing 1-6 of 15 holder rows.
Quick read
ORBIMED ADVISORS LLC leads the comparable SEC ownership view at 6.4%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ORBIMED ADVISORS LLC's linked filing trail.
Comparable ownership
Top 5
ORBIMED ADVISORS LLC
6.4%
RA CAPITAL MANAGEMENT, L.P.
5.4%
PRICE T ROWE ASSOCIATES INC /MD/
0.57%
BlackRock Finance, Inc.
0.54%
Alyeska Investment Group, L.P.
0.42%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13F
Company
|
6.4%
|
$42,282,000
3,409,865 shares
|
— | 31 Mar 2018 |
| RA CAPITAL MANAGEMENT, L.P. |
13F
Company
|
5.4%
|
$35,429,000
2,857,143 shares
|
— | 31 Mar 2018 |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
Company
|
0.57%
|
$3,793,000
305,850 shares
|
— | 31 Mar 2018 |
| BlackRock Finance, Inc. |
13F
Company
|
0.54%
|
$3,577,000
288,469 shares
|
— | 31 Mar 2018 |
| Alyeska Investment Group, L.P. |
13F
Company
|
0.42%
|
$2,771,000
223,438 shares
|
— | 31 Mar 2018 |
| AWM Investment Company, Inc. |
13F
Company
|
0.4%
|
$2,645,000
213,317 shares
|
— | 31 Mar 2018 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2018
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
37
Shares
8,090,838
Rows available
37
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2018 vs Q1 2018 Across Filers
Q1 2018 holders
37
Q2 2018 holders
37
Holder diff
0
| Investor | Q1 2018 Shares | Q2 2018 Shares | Share Diff | Share Chg % | Q1 2018 value | Q2 2018 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend